The Pathologist’s Post

🔬 Did you know that only a handful of liquid biopsy-based diagnostic tools have been approved by the FDA, even though scientists started researching them decades ago? A non-invasive method, they have the potential to revolutionise medical diagnostics, but there are still several obstacles to overcome. For our October newsletter, we had the pleasure of speaking to Sylvain Perriot, Founder of Lermed, about how liquid biopsies work and why they’ll be crucial as we enter the era of personalised medicine. 👉 Check out his insights in the full article here: https://lnkd.in/ewStYgbD

Clinical trial enrollment faces many challenges.  Fortunately, innovative solutions are being implemented to quickly identify and activate the right patients. Join experts from Genome Medical, xCures, and AutoCruitment as they discuss how #biopharma sponsors are implementing these solutions to activate patient clinical trial enrollment. REGISTER NOW: https://lnkd.in/gRg3gwC4

Prior to the FDA Advisory Committee's Meeting of the Peripheral and Central Nervous System Drugs which took place on June 10th we asked our Academic and our Community physician panels some key questions to gauge their sentiment around important aspects of this meeting which included: ·       Clinical Trial Design Concerns ·       Clarifications Hoped for During the Meeting ·       Current Safety Concerns ·       New Safety Information Desired ·       Comparative Insights with Lecanemab ·       Expectations for FDA Advisory Committee Meeting Outcome ·       Thoughts on Public Opinion Alignment Overall, academic physicians displayed more concerns about trial design and generalizability, emphasizing the need for further data and independent analysis. In contrast, community physicians were generally more positive about the trial design but focused on practical challenges in clinical application, such as the availability of tau PET imaging. Both groups expressed significant safety concerns, particularly about ARIA, but community physicians seemed more confident in their ability to manage these risks based on past experiences. Public opinion and expectations for the FDA meeting were similarly cautious but hopeful for approval, with both groups recognizing the importance of clear communication to address public and patient concerns. #FDAAdcomm #donanemab #AlzheimersTreatment #FDAnews

Clinical trial enrollment faces many challenges.  Fortunately, innovative solutions are being implemented to quickly identify and activate the right patients. Join experts from Genome Medical, xCures and AutoCruitment as they discuss how #biopharma sponsors are implementing these solutions to activate patient clinical trial enrollment. REGISTER NOW ⤵ https://lnkd.in/gRg3gwC4

In Clinical Lab Products, partner Joyce Gresko shares insight on #FDA’s final rule for lab-developed tests, and what it means for the clinical diagnostics industry. #healthlaw https://bit.ly/3UDT7FS

As inclusion/exclusion criteria for clinical trials get ever more complex, it has become even more difficult to identify and activate eligible participants. And for rare disease, when most health systems may only see 1-2 patients if any, finding the right patients is a daunting challenge that can delay getting needed therapeutics to market. Join me, Jill Pellegrino, and Bryan Federowicz as we discuss how each of our organizations are solving these challenges.

Engaging the right patients at the right time for the right study takes technology, expertise and experience. Make sure to tune in for this informative session featuring xCures , AutoCruitment , and Genome Medical. #patientcentric #clinicaltrials #patientengagement #RWD

Are you experiencing bladder pain? Join the American Institute of Research's clinical trials! Get Study-Related Medication and compensation for your time, travel, and expenses. Contribute to medical research and help discover new treatments. Learn more at https://bit.ly/3WozQt3 #AmericanInstitudeOfResearch#BladderPain #ClinicalTrials #MedicalResearch

If you work in a clinical lab and haven't had a chance to "browse" the FDA's 500-page final rule on LDTs, then join us on May 30 for a webinar that will identify immediate key steps to consider. ** This will not be an overview of the rule 👍👍 #clinicallaboratory #FDA

I hope many of you who are interested in clinical pharmacogenomics, testing and implementation, will be able to join us for this free ARUP quarterly webinar. I will speak not only based on my own experiences and perspectives in clinical PGx testing but will represent several of my colleagues at ARUP Laboratories and many more from several professional societies who have been so passionate about advancing and advocating for clinical PGx into patient care. It is an effort by many! 💊💊💊💊💊💊💊💊💊 #drugresponse #Pharmacogenetics #labmedicine #ARUPLaboratories